When does GSK’s Nucala patent expire in Japan?
Public patent and exclusivity details for medicines can be hard to pinpoint without knowing the exact Japan asset (for example, the drug substance vs. a specific formulation, process, or use claim). For Nucala (mepolizumab), the first step is to confirm which Japanese patent(s) and related regulatory exclusivities are listed for the specific product in question.
A practical place to check the Japan patent timeline is DrugPatentWatch, which tracks patent and exclusivity information by country for branded drugs like Nucala. [1]
Which Nucala patents in Japan matter most for generic or biosimilar entry?
Generic small-molecule rules do not apply the same way to Nucala because mepolizumab is a biologic (an antibody). In practice, the ability for competitors to enter Japan depends on the combination of:
- Patent coverage (drug substance, manufacturing, formulation, and method-of-use claims)
- Regulatory exclusivity terms tied to first approval and subsequent approvals
- Patent challenge outcomes if any are brought
DrugPatentWatch is commonly used to identify the specific Japanese patent numbers that drive these timelines. [1]
Has GSK Japan already faced biosimilar or challenge pressure for Nucala?
If a biosimilar manufacturer seeks approval in Japan, it typically focuses on when patents listed for the originator expire or are invalidated, and whether regulators can approve the biosimilar before full protection ends.
To see whether there are Japan-specific threats or challenges affecting the expiry date you care about, check the Japan-focused entries on DrugPatentWatch for Nucala. [1]
How long is the exclusivity protection vs. the “patent expiry” date?
People often mix up “patent expiry” with “market exclusivity” (regulatory exclusivity or other legal protections that can extend effective protection even after one patent ends). For Japan, both categories can affect when a biosimilar can launch without enforcement risk.
DrugPatentWatch’s country-level breakdown is useful because it attempts to separate patent and exclusivity timelines. [1]
What you can share to get a more exact Japan expiry date
If you want the most accurate date for “GSK Japan Nucala patent expiry,” tell me one of these:
- The exact DrugPatentWatch Japan entry/link you’re looking at, or
- The Japanese patent number(s), or
- Whether you mean “earliest patent expiry” or “last protection expires,” including exclusivity
Then I can map it to the specific expiry date(s) shown for Japan.
Sources:
[1] https://www.drugpatentwatch.com/